Mnova BioHOS

Significance of the Topic

Nuclear magnetic resonance fingerprinting offers a direct measure of higher order structure for monoclonal antibodies, a critical determinant of their biological activity and therapeutic efficacy. Changes in conformation or dynamics can compromise drug performance, making robust analytical methods essential for quality control.

Objectives and Overview

This application note describes the development of the Mnova BioHOS software suite within MestReNova to streamline 2D NMR fingerprint analysis of monoclonal antibodies. It outlines validation steps, processing workflows, and three core comparison methods: ECHOS, CCSD, and PCA.

Methodology and Instrumentation

• Sample preparation and validation: buffers, excipient compatibility, temperature tolerance, and concentration checks.
• NMR experiments: natural-abundance 1H-13C HSQC on 700–900 MHz spectrometers with optimized parameters, non-uniform sampling, and noise reduction.
• Software platform: Mnova BioHOS for data processing, interactive analysis region selection, and automated fingerprinting routines.

Main Results and Discussion

• Validation confirmed reproducible spectra at 37 °C versus 25 °C, ensuring sample integrity under test conditions.
• ECHOS analysis yielded correlation coefficients (R) of 0.935 for identical-temperature spectra and 0.785 for spectra at 37 °C vs 25 °C, with heat maps highlighting local peak shifts and line broadening.
• CCSD mapping matched 80 key methyl resonances between reference and test spectra, quantifying combined chemical shift differences and amplitude changes to identify the most perturbed sites.
• PCA of bucketed spectral intensities from multiple reference spectra and elevated-temperature tests produced scores plots that clustered similar conditions and loadings plots that pinpointed discriminating spectral regions.

Benefits and Practical Applications

NMR fingerprinting captures global conformational features of large biopharmaceuticals in a single assay, enabling rapid detection of structural variants and degradation products. Mnova BioHOS integrates acquisition, processing, and multilevel comparison in an intuitive interface suited for R&D and QA/QC environments.

Future Trends and Potential Applications

• Development of model-based reference libraries for automated pass/fail screening.
• Extension to other complex biologics such as fusion proteins and glycoproteins.
• Implementation in regulated quality control workflows for lot release testing.
• Leveraging ultra-high-field NMR and cryogenically cooled probes to shorten acquisition times and improve sensitivity.

Conclusion

Mnova BioHOS provides a robust, user-friendly solution for 2D NMR fingerprint analysis of monoclonal antibodies, demonstrating sensitivity to subtle higher order structural changes. The ECHOS, CCSD, and PCA workflows offer complementary metrics for comprehensive quality assessment.

Reference

Selected bibliography includes key studies on NMR fingerprinting of mAbs and HOS analysis published in J. Pharm. Biomed. Anal., Anal. Chem., MAbs, and J. Pharm. Sci.